Author(s):
Smita S. Aher, Saroj P. Gajare, Ravindra B. Saudagar
Email(s):
sarojgajare19@gmail.com
DOI:
10.5958/0974-360X.2017.00573.X 
Address:
Smita S. Aher1, Saroj P. Gajare2, Ravindra B. Saudagar1
1Department of Pharmaceutical Chemistry, R. G. Sapkal College of Pharmacy, Anjaneri, Nasik.
2Department of Quality Assurance Techniques, R. G. Sapkal College of Pharmacy, Anjaneri, Nasik.
*Corresponding Author
Published In:
Volume - 10,
Issue - 9,
Year - 2017
ABSTRACT:
Diabetes mellitus is a chronic condition prevalent worldwide. It is estimated that more than 246 million individuals have diabetes, with this number expected to increase to 366 million by the year 2030. The chronic hyperglycemia of diabetes is associated with long term damage to various organs, including the eyes, kidneys, nervous system, heart, and vasculature. India has a long history regarding the epidemiology of diabetes. In an effort to optimize glycemic control and also to reduce the burden of diabetic complications, several classes of oral hypoglycemic agents have been developed. Linagliptin has now been on the market and has been established as the first-line agent of choice for the management of type 2 diabetes. In this way, linagliptin is anticipated to reduce insulin resistance, contribute to weight loss, and play a significant role in the improvement of cardiovascular outcomes.
Cite this article:
Smita S. Aher, Saroj P. Gajare, Ravindra B. Saudagar. Linagliptin: A Review on Therapeutic Role in Diabetes Mellitus. Research J. Pharm. and Tech. 2017; 10(9): 3233-3236. doi: 10.5958/0974-360X.2017.00573.X
Cite(Electronic):
Smita S. Aher, Saroj P. Gajare, Ravindra B. Saudagar. Linagliptin: A Review on Therapeutic Role in Diabetes Mellitus. Research J. Pharm. and Tech. 2017; 10(9): 3233-3236. doi: 10.5958/0974-360X.2017.00573.X Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2017-10-9-73